Recent work has shown that limited lowering of the postprandial blood glucose level caused by the presence of polymorphisms in SGLT1 in specific human subpopulations led to long-term beneficial effects, reducing the incidence of diabetes, obesity, heart failure and mortality (Seidelmann et al., 2018). The gene discussed is SLC5A1; the disease is heart failure.